58487-55-1

Upstream product

• 13794-72-4 6,7-dimethoxy quinazolin-4-one 
• 26961-27-3 2-amino-4,5-dimethoxybenzonitrile 
• 98-80-6 phenylboronic acid 
• 39996-22-0 (2-amino-4,5-dimethoxyphenyl)-(phenyl)methanone 
• 67-68-5 dimethyl sulfoxide 
• 13790-39-1 6,7-dimethoxy-4-chloroquinazoline 
• 77287-34-4 formamide 

Downstream Products

• 1006890-32-9 6-methoxy-4-phenylquinazolin-7-ol 

Relevant academic research and scientific papers

Pure red phosphorescent iridium(iii) complexes containing phenylquinazoline ligands for highly efficient organic light-emitting diodes

Two novel heteroleptic iridium complexes containing 4-phenylquinazoline (pqz) as a cyclometalating ligand, namelyIr1andIr2, are designed and synthesized. Methoxy groups are incorporated into the 6- and 7-sites of pqz rings to tune the physical properties

“On-Water” Palladium-Catalyzed Tandem Cyclization Reaction for the Synthesis of Biologically Relevant 4-Arylquinazolines

The quinazoline scaffold is prevalent in pharmaceutically relevant molecules that show diverse biological activities. Herein, we report an efficient “on-water” palladium-catalyzed tandem cyclization reaction from commercially available arylboronic acids and benzonitriles that enable the rapid access to 4-arylquinazoline scaffolds in good to excellent yields (45 examples, up to 98 % yield). This protocol has shown good functional group tolerance and broad substrate scope. The reaction was also performed on a gram scale and successfully applied to the synthesis of the highly potent and selective PI3Kδ inhibitor N11, showing the practicability and synthetic utility of the protocol. In this reaction, the quinazoline scaffold is efficiently constructed with the simultaneous formation of one C?C bond and one C?N bond. Collectively, the protocol could serve as an alternative strategy to synthesize biologically important quinazoline scaffolds.

4-arylquinazoline compounds and preparation method thereof

The invention provides 4-arylquinazoline compounds which have a general formula as shown in the specification, wherein R represents hydrogen, halogen, alkane, nitro or alkoxy, R represents hydrogen or methyl, Ar represents groups as shown in the specification, and R represents hydrogen, halogen, alkane, alkoxy, nitro, hydroxy, trifluoromethyl, phenyl or methoxycarbonyl; the compounds enrich the structures of 4-arylquinazoline compounds, and provide a material basis for further study on the potential biological activity of the compounds. The invention also provides a preparation methodof the compounds, which comprises the following step: cyanophenyl raw materials react with aromatic phenylboronic acid ArB(OH)2 in a sealed environment under the action of a palladium salt catalyst,a bidentate chelating ligand, a Lewis acid and a solvent at 30-300 DEG C to form the 4-arylquinazoline compounds; a structural formula of the 4-arylquinazoline compounds is shown in the specification,and the preparation method provided by the invention has the advantages of no need of inert gas protection, mild reaction conditions, short reaction time, high yield and the like.

One-pot three-component synthesis of quinazolines: Via a copper-catalysed oxidative amination reaction

A copper-catalysed three-component reaction for constructing a series of quinazoline derivatives has been developed. In this system, solvents act as the reactants and different functional groups are well tolerated to obtain corresponding products in moderate to good yields.

Asymmetric hydrogenation of quinazolinium salts catalysed by halide-bridged dinuclear iridium complexes bearing chiral diphosphine ligands

Asymmetric hydrogenation of quinazolinium salts was catalysed by halogen-bridged dinuclear iridium complexes bearing chiral diphosphine ligands, yielding tetrahydroquinazoline and 3,4-dihydroquinazoline with high enantioselectivity. A derivative of chiral dihydroquinazoline was used as a chiral NHC ligand. This journal is

HETEROAROMATIC QUINOLINE-BASED COMPOUNDS

The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds which are selective inhibitors of PDE10. The invention further relates to intermediates for preparation of such compounds; pharmaceutical compositions comprising such compounds; and the use of such compounds in methods for treating certain central nervous system (CNS) or other disorders. The invention relates also to methods for treating neurodegenerative and psychiatric disorders, for example psychosis and disorders comprising deficient cognition as a symptom.

o-Aminophenyl Alkyl/Aralkyl Ketones and Their Derivatives: Part V -- An Efficient Synthetic Route to Some Biologically Active 4-Substituted Quinazolines

4-Substituted quinazolines (II) have been prepared by the action of formamide on o-aminophenyl alkyl and aralkyl ketones (I) in the presence of borontrifluoride etherate as catalyst, and tested for their inotropic activity.